StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Anthera Pharma's (ANTH) Blisibimod Receives FDA Orphan Drug Status
August 9, 2017 6:25 AM
Anthera Pharma' (NASDAQ: ANTH) Blisibimod received FDA orphan drug status for treatment of patients with immunoglobulin A ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q
August 11, 2017 8:08 AM
Anthera Pharma (ANTH) Confirms FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
August 9, 2017 4:01 PM